Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1182/blood-2002-04-1168 | DOI Listing |
Asian J Transfus Sci
September 2022
Department of Blood Bank, Regency Hospital Limited, Kanpur, Uttar Pradesh, India.
Karl Landsteiner discovered ABO blood group system in the early 20 century, but still, uncertainty remains in immunohematology while detection of ABO subgroups or weaker variants. The presence of weak subgroups in patient samples gives rise to the discrepancy in forward (cell) and reverse (serum) grouping. We here report a case of the B(A) phenotype in a patient who was diagnosed with chronic liver disease with acute pancreatitis, requiring packed red blood cells due to anemia.
View Article and Find Full Text PDFAsian J Transfus Sci
November 2023
Department of Transfusion Medicine, Apollo Multispeciality Hospitals, Kolkata, West Bengal, India.
Background: Examples of group B red cells that react weakly or not at all with anti-B have been described. Subgroups of B such as B, B, B, and B are rare and are less frequently reported. We studied the frequency of subgroups of B in our healthy blood donor population and serologically characterized and differentiated these subgroups.
View Article and Find Full Text PDFAsian J Transfus Sci
September 2022
Department of Transfusion Medicine and Immunohaematology, St. John's Medical College, Bengaluru, Karnataka, India.
Background: Although ABO and RhD are the clinically significant blood group antigens that are routinely tested for, other blood group antigens may become important in multiply transfused patients due to risk of alloimmunization. Knowledge of antigen prevalence in a population is important in the context of alloimmunization and antigen matching. This study aims to do the same in a population of voluntary blood donors of a center in South India.
View Article and Find Full Text PDFAsian J Transfus Sci
October 2024
Department of Transfusion Medicine, Sri Balaji Action Medical Institute, New Delhi, India.
Background: High titers of anti-A and anti-B are considered to be one reason for hemolytic transfusion reactions and ABO hemolytic disease in fetus and neonates. There is no consensus for critical ABO antibody titers to guide transfusion or transplant decisions. Implementation of ABO titer measurement can favor reduction in transfusion reactions in nongroup "O" recipients.
View Article and Find Full Text PDFAsian J Transfus Sci
May 2023
Department of Transfusion Medicine, Saveetha Medical College and Hospitals, Chennai, Tamil Nadu, India.
Hemolytic disease of foetus and newborn (HDFN) is a disease characterized by the destruction of fetal red cells by the maternal antibodies which occurs due to allo immunization in the mother by feto-maternal blood group incompatibility. The antibodies most frequently implicated in HDFN may vary depending on the demographic location under consideration. In areas where RhIg administration is available, ABO antibodies are more commonly implicated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!